P. Holvoet et al., MALONDIALDEHYDE-MODIFIED LOW-DENSITY LIPOPROTEINS IN PATIENTS WITH ATHEROSCLEROTIC DISEASE, The Journal of clinical investigation, 95(6), 1995, pp. 2611-2619
The murine monoclonal antibody mAb-1H11 raised against malondialdehyde
(MDA)-modified LDL, was used to detect cross-reacting material in hum
an atheromatous tissue and in plasma, MDA-modified LDL levels in plasm
a were 0.19+/-0.02 mg/dl (mean+/-SEM) in 44 control subjects, 0.24+/-0
.02 mg/dl in 15 patients with chronic stable angina pectoris (P = NS v
s LDL cholesterol matched controls), 1.4+/-0.1 mg/dl in 60 patients wi
th acute myocardial infarction (P < 0.001 vs controls), and 0.86+/-0.1
1 mg/dl in 22 patients with carotid atherosclerosis (P < 0.001 vs cont
rols), Modified LDL, isolated from pooled LDL of 10 patients, showed a
higher electrophoretic mobility on agarose gels, a higher content of
thiobarbituric acid reactive substances, and a higher cholesterol/prot
ein ratio than native LDL and had a similar reactivity (antigen/protei
n ratio) in the assay as the in vitro MDA-modified LDL used for calibr
ation, Its apo B-100 moiety was not fragmented, Uptake of this modifie
d LDL by macrophages resulted in foam cell generation, In conclusion,
elevated plasma levels of atherogenic MDA-modified LDL may be a marker
for unstable atherosclerotic cardiovascular disease.